Anaplastic lymphoma kinase trang 1 tải miễn phí từ TAILIEUCHUNG

"Anaplastic lymphoma kinase" trang 1 - tải miễn phí từ Tailieuchung

Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma

Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma

11 40 1

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: Study protocol of the ABP trial

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: Study protocol of the ABP trial

10 36 1

Frequency of anaplastic lymphoma kinase rearrangements in Moroccan patients with non small cell lung cancer: A multiinstitutional national retrospective study

Frequency of anaplastic lymphoma kinase rearrangements in Moroccan patients with non small cell lung cancer: A multiinstitutional national retrospective study

5 76 0

Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

8 35 1

The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: A meta-analysis of clinical trials

The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: A meta-analysis of clinical trials

6 37 1

A retrospective study of alectinib versus ceritinib in patients with advanced non– small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

A retrospective study of alectinib versus ceritinib in patients with advanced non– small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

8 44 1

Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models

Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models

15 8 1

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced nonsmall cell lung cancer: A meta-analysis

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced nonsmall cell lung cancer: A meta-analysis

16 88 0

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC

10 66 1

Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset

Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset

10 28 1

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation

5 28 1

Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations

Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations

8 14 1

Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: A systematic review and secondary analysis of trials

Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: A systematic review and secondary analysis of trials

17 72 0

ALK-rearranged lung squamous cell carcinoma responding to alectinib: A case report and review of the literature

ALK-rearranged lung squamous cell carcinoma responding to alectinib: A case report and review of the literature

5 56 1

RNA-based analysis of ALK fusions in nonsmall cell lung cancer cases showing IHC/ FISH discordance

RNA-based analysis of ALK fusions in nonsmall cell lung cancer cases showing IHC/ FISH discordance

9 33 1

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

9 47 1

Post-crizotinib management of effective ceritinib therapy in a patient with ALKpositive non-small cell lung cancer

Post-crizotinib management of effective ceritinib therapy in a patient with ALKpositive non-small cell lung cancer

5 53 1

Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed

Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed

8 25 1

Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity

Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity

9 30 1

Extraordinary response to crizotinib in a woman with squamous cell lung cancer after two courses of failed chemotherapy

Extraordinary response to crizotinib in a woman with squamous cell lung cancer after two courses of failed chemotherapy

4 33 5

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.